Implant-Mediated Therapy of Arterial Hypertension.

ABSTRACT: PURPOSE OF REVIEW:To give an overview on recent developments in permanent implant-based therapy of resistant hypertension. RECENT FINDINGS:The American Heart Association (AHA) recently updated their guidelines to treat high blood pressure (BP). As elevated BP now is defined as a systolic BP above 120 mmHg, the prevalence of hypertension in the USA has increased from 32% (old definition of hypertension) to 46%. In the past years, device- and implant-mediated therapies have evolved and extensively studied in various patient populations. Despite an initial drawback in a randomized controlled trial (RCT) of bilateral carotid sinus stimulation (CSS), new and less invasive and unilateral systems for baroreflex activation therapy (BAT) with the BAROSTIM NEO® have been developed which show promisi

SUBMITTER: Gierthmuehlen M 

PROVIDER: S-EPMC7005062 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature